Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCieloPCLOF -19.03% 3-Year EBITDA Growth Rate is 41.10% as of Dec. 2025, which is at its 10-year median of 41.10. The stock has 5 warning signs investors should review. Among 814 Drug Manufacturers companies, PharmaCielo ranks better than 85.87% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 40.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of PharmaCielo was 44.00% per year. The lowest was 39.70% per year. And the median was 41.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PharmaCielo 3-Year EBITDA Growth Rate Related Terms
PCLOF vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PharmaCielo's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 41.10% mean?
PharmaCielo (PCLOF) has a 3-Year EBITDA Growth Rate of 41.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PharmaCielo and its competitors. This is near median its historical median of 41.10. Over the past decade, PharmaCielo's 3-Year EBITDA Growth Rate has ranged from 39.70 to 44.00. According to the industry distribution chart, PharmaCielo ranks #115 out of 814 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is PharmaCielo's 3-Year EBITDA Growth Rate too high?
PharmaCielo's current 3-Year EBITDA Growth Rate of 41.10% is near median its 10-year median of 41.10. Over the past 10 years, this metric has ranged from a low of 39.70 to a high of 44.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. PharmaCielo's value of 41.10% is 361.8% above this industry median. Based on the distribution chart, PharmaCielo ranks #115 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does PharmaCielo's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #115 out of 814 companies for 3-Year EBITDA Growth Rate. This places PharmaCielo in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. PharmaCielo's value of 41.10% is 361.8% above this benchmark. Historically, PharmaCielo's own 3-Year EBITDA Growth Rate has ranged from 39.70 to 44.00 over the past decade. While the company's 10-year median is 41.10 vs. the industry median of 8.90, PharmaCielo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current 3-Year EBITDA Growth Rate of 41.10% is 361.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PharmaCielo and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current 3-Year EBITDA Growth Rate is 41.10%, which is near median its own 10-year median of 41.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.09, compared to a current price of $0.05 — trading 48.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 41.10%, which is near median its 10-year median of 41.10 and 361.8% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current 3-Year EBITDA Growth Rate is 41.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 
